Schedule-Dependent Synergistic Effect of Pemetrexed Combined with Gemcitabine against Malignant Pleural Mesothelioma and Non-Small Cell Lung Cancer Cell Lines

Shinjiro Nagai,Kazumasa Takenaka,Makoto Sonobe,Hiromi Wada,Fumihiro Tanaka

Schedule-Dependent Synergistic Effect of Pemetrexed Combined with Gemcitabine against Malignant Pleural Mesothelioma and Non-Small Cell Lung Cancer Cell Lines

2008

Shinjiro Nagai
Kazumasa Takenaka
Makoto Sonobe
Hiromi Wada
Fumihiro Tanaka

Background: Pemetrexed, a multi-targeted antifolate (MTA), is a promising agent in the treatment of malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC). With

Keywords:

Pemetrexed
Mesothelioma
Cell
Cell cycle
Combination therapy
Oncology
Gemcitabine
Lung cancer
Antifolate
Medicine
Internal medicine
lung cancer cell
non small cell
pleural mesothelioma
combination chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations